Recent genetic studies yielded conflicting results regarding a role for the variant chromogranin B (CHGB) P413L allele as a disease modifier in ALS. Moreover, potential deleterious effects of the CHGB P413L variant in ALS pathology have not been investigated. Here we report that in transfected cultured cells, the variant CHGB L413 protein exhibited aberrant properties including mislocalization, failure to interact with mutant superoxide dismutase 1 (SOD1) and defective secretion. The CHGB L413 transgene in SOD1 G37R mice precipitated disease onset and pathological changes related to misfolded SOD1 specifically in female mice. However, the CHGB L413 variant also slowed down disease progression in SOD1 G37R mice, which is in line with a very slow disease progression that we report for a Swedish woman with ALS who is carrier of two mutant SOD1 D90A alleles and two variant CHGB P413L and CHGB R458Q alleles. In contrast, overexpression of the common CHGB P413 allele in SOD1 G37R mice did not affect disease onset but significantly accelerated disease progression and pathological changes. As in transgenic mice, the CHGB P413L allele conferred an earlier ALS disease onset in women of Japanese and French Canadian origins with less effect in men. Evidence is presented that the sex-dependent effects of CHGB L413 allelic variant in ALS may
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder characterized by the progressive loss of motor neurons. Most ALS patients die within 2 to 5 years after onset of symptoms since no effective treatment exists. Approximately 90% of ALS cases are sporadic. The most frequent genetic causes of familial ALS are mutations in the gene coding for superoxide dismutase 1 (SOD1) (1, 2) and an expansion of hexanucleotide repeats in noncoding region of C9ORF72 (3, 4) . Rare mutations in many disparate genes including TARDBP, TBK1, NEK1, FUS, ALS2, DCTN1, SETX, VAPB, VEGF, ANG, CHMP2B, VCP, OPTN, PFN1, SQSTM1 and UBQLN2 are also known to be associated with ALS .
Chromogranins, which are major constituents of secretory large dense-core vesicles in neurons, act as chaperone-like proteins that bind mutant SOD1 proteins to promote their secretion (27) . This finding led us to search for chromogranin genetic variations in ALS and control subjects. A few years ago we reported that a common chromogranin B (CHGB) P413L variation was associated with higher risk to develop ALS and with earlier age of onset in both sporadic and familial ALS cases in cohorts of FrenchCanadian origin (28) . However, these results have not been corroborated by other groups that reported a lack of association of CHGB P413L with ALS in other populations from the Netherlands,
France and Italy (29) (30) (31) . Although the divergent results might be explained by population-specific effects, a pathogenic role for the CHGB P413L variant in ALS remains unknown.
Here, we demonstrate a mislocalization and defective binding and secretion of CHGB L413 variant for mutant and misfolded SOD1 in transfected cultured cells. We generated transgenic mice bearing genomic fragments coding for the human CHGB L413 or CHGB P413 variants to derive double transgenic SOD1 G37R mice co-expressing mutant SOD1 and CHGB variants.
The expression of the CHGB L413 transgene in SOD1 G37R mice caused an earlier disease onset and pathological changes specifically in female mice. As in transgenic mice, the sexdichotomous effects of the CHGB P413L variant on the onset of ALS were also observed in ALS cohorts of Japanese and FrenchCanadian origins. Evidence is presented that the sexdichotomous effects of a CHGB L413 allele in ALS are related to enhanced gene expression in females due to a sex-determining region Y (SRY) silencer element in the CHGB promoter.
Results
Defective binding properties of CHGB P413L and CHGB
H230R protein variants
We previously reported that mouse chromogranins can interact with mutant or oxidized SOD1 in vitro (27, 32) . Thus, we investigated the effect of amino acid variation in CHGB L413 on the ability to bind mutant SOD1. In these studies, we also included another rare chromogranin variant, CHGB R230 , detected only in few ALS cases but not in control individuals (28) . We carried out transient co-expression assays in Neuro2a cells using plasmid vectors coding for mouse chromogranin B (mCgB) or various human CHGB species tagged with hemagglutinin (HA) at the carboxy terminus together with vectors coding for wild type (WT) or SOD1
G93A species tagged with FLAG at the amino terminus. As shown in Figure 1A , after co-transfection of vectors in Neuro2a cell, the immunoprecipitation of mutant SOD1
G93A
, but not WT SOD1, with anti-FLAG in cell extracts led to coprecipitation of mouse mCgB or of human CHGB WT (P413/ H230). In contrast, the variants CHGB L413 and CHGB R230 were not co-immunoprecipitated with SOD1
. . The genomic CHGB fragments included 5.1 kb of CHGB promoter region and 13.7 kb of exon/intron sequences (Fig. 1B) . Total cell lysates from transfected cells were fractionated by two-dimensional gel electrophoresis and then transferred to a membrane for immunodetection of CHGB. As shown in Supplementary Material, Figure  S1A , WT CHGB Mislocalization and defective secretion of CHGB L413 and CHGB
R230 variants in cultured cells
To further investigate the localization of CHGB WT and variants in the context of overexpression of human SOD1 species, Neuro2a cells were co-transfected with HA-CHGB species and FLAG-SOD1 species, and then analyzed by double immunofluorescence using antibodies against trans-Golgi marker (TGN38) or synaptic vesicle marker (synaptophysin). Confocal laser microscopy revealed that a large fraction of HA-CHGB WT (67%) was detected with the trans-Golgi marker in cells transfected with HA-CHGB WT alone ( Fig. 2A) . The co-transfection of SOD1 G93A vector reduced the detection of HA-CHGB WT with the trans-Golgi marker (56%) ( Fig. 2A) . Synaptic vesicle markers were located diffusely and partially accumulated in the cytoplasm of Neuro2a cells. Some of the HA-CHGB WT was colocalized with the accumulation of synaptic vesicle marker in cells co-transfected with SOD1 G93A (Fig. 2B, arrowheads) . It is Figure S3C ). As shown in Figure 3C and Supplementary Material, Figure S3D , the CHGB L413 transgene increased ALS disease duration in female SOD1 G37R mice, but not in males. In contrast, overexpression of CHGB P413 did not affect disease onset but it reduced survival and disease duration in both female and male SOD1 G37R mice. The data in Figure 3D , Fig. S4 ). To investigate the degeneration of spinal a-motor neurons, lumbar cord sections at 345 days of age were immunostained with both anti-ChAT and anti-NeuN antibody. The number of a-motor neurons, which were positive for both ChAT and NeuN, in SOD1
G37R
;CHGB L413 and SOD1
;CHGB P413 mice at 345 days of age was similar to age-matched SOD1 G37R mice (Fig. 4B) . A most striking change at this age was the reduced size of a-motor neurons in SOD1
;CHGB L413 female mice (Fig. 4B ).
The levels of misfolded SOD1 species were determined in spinal cord extracts at end stage of disease by immunoprecipitation with anti-misfSOD1 antibody called B8H10 (33) . The overexpression of CHGB P413 or CHGB L413 proteins enhanced the levels of misfSOD1 in SOD1 G37R mice (Fig. 4C ). This effect was more pronounced in female than male mice (Fig. 4C ). The neuromuscular junctions of gastrocnemius muscles were examined at 345 days of age. 
CHGB expression levels are higher in females than males
Interestingly, the immunoblotting results in Figure 5E and Supplementary Material, Figure S5A revealed higher levels of mouse CgB and human CHGB proteins in female mice than in male mice. This sex-dependent CHGB expression was further investigated by in situ hybridization on mouse spinal cord using an antisense probe for CHGB mRNA which did not interact with endogenous mCgB mRNA (Supplementary Material, Fig. S5B ).
As shown in Figure 6A , the CHGB mRNA levels were significantly higher in females than in males. The CHGB mRNA and CHGB protein species were expressed in neurons and not in glial cells of either single or double transgenic mice ( Fig. 6A and B).
The CHGB P413L variant is a modifier of ALS onset for women in some populations
The results of sex dependent effects of CHGB L413 variant for ALS onset in transgenic mice (Fig. 3A) led us to further investigate the effect of CHGB L413 variant as a sex dependent disease modifier of ALS onset in Japanese population (Supplementary Material, Table S2 ). There was no significant difference in the age of onset between the CHGB L413 and CHGB P413 carriers in Japanese ALS patients (62.4 6 0.3 years and 63.8 6 0.1 years, respectively). However, further analyses of this Japanese cohort revealed important sex differences in the ALS onset of the L413 variation. As shown in Figure 7A , Japanese ALS female patients carrying the L413 variant showed an earlier age of ALS disease onset compared to those carrying the P413 variant (62.1 6 0.7 years and 68.4 6 0.3 years, respectively). In contrast, Japanese men with ALS carrying the L413 variant showed the same age of ALS onset as P413 carriers (62.6 6 0.5 years and 61. (Fig. 7B) . In contrast, the L413 variation had only little effect on age of disease onset in men of FrenchCanadian origin having ALS (56.0 6 0.2 years and 60.6 6 0.1 years, respectively). The results from cohorts of Japan and French-Canada origins demonstrated sex-dependent effects of the CHGB L413 variant on ALS onset. However, the L413 variation had no effect on disease onset in ALS cohorts from French (29) or Swedish (26) origins ( Fig. 7C and D) . We further investigated the effect of the CHGB L413 variant for ALS progression in a Swedish FALS family with two patients homogenous for the D90A/D90A SOD1 (Table 1 ) (41, 42) . A female patient is heterozygous for the Q258/L413 CHGB variants and has a remarkably slow progression rate: in 2016, she is alive with a documented disease history of 28 years and an ALSFRS of 24/40, making her one of the longest surviving ALS patients known. The patient is not taking riluzole and is not using mechanical ventilatory support. However, contrasting this, her sister died of respiratory failure 18 years after onset. The sister carried the common WT (R258/P413) CHGB alleles (Table 1) . This family observation is in line with CHGB variants acting as disease modifiers of ALS progression as presented in SOD1-transgenic mice (Fig. 3B ).
Discussion
The results presented here demonstrate sex-dependent effects of the allelic variant CHGB P413L on onset of ALS. The overexpression of CHGB L413 transgene in SOD1 G37R mice precipitated disease onset specifically in female mice, but not in male mice (Fig. 3A) . Furthermore, sex-dichotomous effects of the CHGB P413L variation on ALS onset were also observed in Japanese and French-Canadian origin populations ( Fig. 7A and  B) . Hence, women carrying the CHGB L413 variation exhibited an earlier onset of disease compared to those carrying only the CHGB P413 alleles in these ALS populations. The CHGB L413 variation had only minor effect on age of disease onset in ALS men.
Although there was no mutant SOD1-FALS in our Japanese and French-Canadian subjects, an involvement of SOD1-mediated pathogenic mechanism is a possibility because aggregates of misfolded SOD1 species have regularly been detected in both sporadic ALS (SALS) and familial ALS (FALS) patients (43-45), and not only in neurons but also in glia cells (46 (Fig. 1B) . It has been reported that the SRY on chromosome Y acts on the SRY region of the CHGB promoter reducing its activity (47) . We find that SRY is immunodetected in spinal cord neurons of male mice (Supplementary Material, Figure S5C ). Moreover, SRY is expressed in neurons of the brain and spinal cord of men and of male mice according to the gene expression data in the Allen Brain Atlas (http://www.brain-map.org). SRY has been reported to regulate directly catecholamine synthesis and metabolism in the midbrain (48, 49) . A search for sequence homologies revealed that the sequence of HMG-box region, which interacts to the SRY region of CHGB promoter, showed high homology between mouse and human SRY (Supplementary Material, Table S3 ). These results suggest that the mouse SRY can interact with the SRY region in the promoter of a human CHGB transgene to reduce its expression. Accordingly, a higher expression of CHGB occurred in females transgenic mice as determined by in situ hybridization with the antisense probe specific for CHGB (Fig. 6A) . From these results, we conclude that higher expression levels of CHGB in female SOD1 G37R mice account for the sexdichotomous effects of CHGB P413L variation in precipitating disease onset, ER stress induction and loss of neuromuscular junctions (Figs. 3A, 4D , 5B-E). Surprisingly, the overexpression of the CHGB L413 transgene precipitated disease onset without affecting survival of SOD1 G37R mice (Fig. 3A and B) . In contrast, overexpression of CHGB P413 transgene did not affect disease onset but it reduced survival of SOD1 G37R mice (Fig. 3A-C) . How to explain the differential effects of CHGB L413 and CHGB P413 genes on ALS pathogenesis in the mouse model? Our results demonstrate that CHGB P413 protein can interact with mutant and misfSOD1 to enhance secretion of misfSOD1 ( Fig. 1 and 2C) . Accordingly, increasing the levels of extracellular misfSOD1 would increase microgliosis with ensuing motor neuron damage (27) . Because of sex differences in CHGB expression levels, the microgliosis in the SOD1 G37R ;CHGB P413 mice was more prominent in females than males (Fig. 4A) . Enhanced microgliosis is expected to influence disease progression without affecting disease onset (50) . Therefore, enhanced secretion of misfSOD1 may explain why overexpression of CHGB P413 proteins accelerated disease progression after onset. Conversely, the CHGB L413 variant, which is unable to bind and to stimulate secretion of misfSOD1 in the milieu ( Fig. 1 and 2C ), enhanced disease onset suggesting that it may exert toxicity within motor neurons to enhance disease susceptibility (50) . Accordingly, expression of CHGB L413 in transfected Neuro2A cultured cells caused secretion defects and impaired neurite outgrowth (Fig. 2C , Supplementary Material, Figure S2 ). Moreover, expression of the CHGB L413 transgene in female SOD1 G37R enhanced the loss of neuromuscular junctions (Fig. 4D) , and it increased ER stress and misfolded SOD1 levels in spinal motor neurons (Fig. 5) . The overexpression of CHGB L413 transgene prolonged disease duration in female SOD1 G37R mice compared to female bearing the CHGB P413 transgene (Fig. 3C ). An association of CHGB variants with very long disease duration was also observed in ALS sisters homozygous for the SOD1 D90A mutation (Table 1) .
In summary, the results presented here suggest that CHGB variant alleles, the rare CHGB L413 and common CHGB
P413
, may act as modifiers of ALS disease dependent on their expression levels which is higher in females because of a sex-determining region Y element in the CHGB gene promoter. Expression of CHGB L413 variant in SOD1 G37R mice precipitated disease onset (Fig. 3A) , but it also slowed down disease progression likely by restraining neuronal secretion of misfolded SOD1 in the milieu thereby attenuating microgliosis (Figs. 2C, 3B and C, 4A). In contrast, expression of the common CHGB P413 allele in SOD1 G37R mice exacerbated disease progression after onset most likely by increasing secretion of misfolded SOD1 and ensuing microgliosis (Figs. 2C, 3B and C, 4A). In view of the distinct modifier effects of the common and rare CHGB variants on ALS pathogenesis caused by SOD1 mutation, it would be of interest to further investigate whether CHGB allelic variants might act as sex-modifiers in the ALS disease caused by other gene mutations and in TDP-43 proteinopathies. Since the L413 variation had no effect on disease onset in French and Swedish ALS cohorts unlike Japanese and French Canadian cohorts (Fig. 7) , the divergent results might be explained by population-specific effects. Additional examinations of the L413 variation for other ALS populations will be needed to confirm this point.
Materials and Methods

Antibodies
The following antibodies were used in this study: anti-FLAG (M2, Sigma Aldrich, St. Louis, MO), anti-HA (H6908, Sigma;3F10, Roche, Mannheim, Germany), anti-SOD1 (SOD100, Enzo Life Science, Farmingdale, NY; C17, Santa Cruz Biotechnology, Santa Cruz, CA), anti-chromogranin B (26102, QED Bioscience, San Diego, CA; PA1-10839, Thermo, Rockford, IL), B8H10 (33), C4F6 (37), anti-TGN38 (M290, Santa Cruz), anti-synaptophysin (D35E4, Cell signaling technology, Danvers, MA), anti-synaptotagmin V (46, Santa Cruz), anti-Akt1 (B1, Santa Cruz), anti-Mac2 
Plasmids, cell culture and transfection
Mammalian expression plasmid carrying the human SOD1 (WT or G93A) tagged with FLAG (pcDNA3-FLAG-hSOD1), human CHGB (WT, P413L or H230R) tagged with HA (pcDNA3-CHGB-HA) were generated as previously described (27) . The plasmid carrying CHGB fragment (P413 or L413) was generated (pBluescript-CHGB). Briefly, the human BAC clone RP11-518C18 containing the complete CHGB gene was used to amplify a 18.8 kb genomic fragment by PCR using a high fidelity polymerase (NEB). The CHGB fragment which contains promoter and coding sequence (exons and introns) was inserted into pBluescript. The P413L mutation was inserted into the genomic sequence using sitedirected mutagenesis and the final clone was completely sequenced. Murine neuroblastoma cell line, Neuro 2a cells were maintained in Dulbecco's modified essential medium (DMEM) containing 10% fetal bovine serum (27, 32) . Transfections were performed using Lipofectamin 2000 (Invitrogen) according to the manufacturer's protocol. At 24 h after transfection, the medium was replaced with the nutrient medium containing 5 mmol/l dibutyryl cAMP (Sigma) and antibiotics. At 48 h after transfection, cells were exposed to 1.5 mmol/l H 2 O 2 for 30 min for the analysis of ER stress markers.
Subcellular fractionation of cultured cells
Following exposure to H 2 O 2 , cells were washed in cold PBS and then scrapped in cold PBS containing 1 mmol/l EDTA. The cells were harvested by centrifugation at 700 g for 5 min. After the centrifugation, the pellet was resuspended in a lysis buffer consisting of 10 mmol/l HEPES pH 8.0, 50 mmol/l NaCl, 0.1 mmol/l EDTA, 0.5 mol/l sucrose, 0.5% Triton X-100, protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Pierce Biotechnology) and incubated on ice for 5 min. The supernatants were centrifuged at 1,000 g for 10 min. After protein determination was performed by the Bradford method (Bio-Rad Laboratories, Hercules, CA), the supernatant was used as the extranuclear (cytosolic/membrane) fractions for the analysis of ER stress markers (51) .
Immunoblotting and immunoprecipitation of cultured cells
At 48 h after transfection, cells were lysed in TNT-G buffer consisting of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, and 1% Triton-X100 with protease inhibitor cocktail (Roche). After 30 min incubation on ice, the cell suspension was centrifuged (20,000 g for 20 min) and the supernatant was collected.
The cell lysates were incubated with anti-FLAG M2 agarose affinity gel (Sigma) at 4 C overnight and were eluted with 4% SDS sample buffer (27) . For the analysis of ER stress markers, the samples of subcellular fraction were used. Samples were resolved by SDS-PAGE and transferred to a PVDF membrane (Polyscreen, PerkinElmer, Boston, MA). A western blot image was obtained using a chemiluminescence detection kit (Pierce Biotechnology, Rockford, IL).
Immunocytochemistry
Cultured cells were fixed by 4% paraformaldehyde (PFA) for 30 min and cold Methanol for 20 min at room temperature, and were incubated with PBS containing 10% serum and 0.2% Triton-X100 for 1 h at room temperature for blocking. After blocking, cells were incubated with primary antibodies diluted in PBS containing 5% normal goat serum at 4 C overnight and subsequently with corresponding fluorescent secondary antibodies (Alexa, Invitrogen). Samples were observed by an investigator blinded to the genotype using confocal laser microscopy (FV300, Olympus, Tokyo, Japan) and the images were analyzed by the use of Image J.
The analyses of CHGB mislocalization and neurite outgrowth in cultured cells
For the calculation of CHGB percentages colocalizing with TGN-38 (trans-Golgi marker), the merged and unmerged CHGB vesicles with TGN-38 marker were analyzed. More than 40 cells were analyzed for each condition (28) . For the analysis of the percentage of cells expressing neurites, average number of neurites per cell, and average length of neuritis, cells with neurites were defined as cells that possessed at least one neurite of greater than the diameter of the cell body (52) (53) (54) . The data presented are the mean of three individual transfected 2 cm 2 dishes and are representative of three independent experiments. At least 100 cells per transfection were scored for neurite outgrowth.
Secretion assays
At 24 h after transfection, Neuro2a cells plated onto a 6-well culture dish were washed in PBS twice. Cells were incubated in basal secretion medium consisting of 10 mM HEPES, 129 mM NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM MgCl2, 1.2 mM KH2PO4, 1 mM CaCl2 and 2.8 mM glucose (pH 7.4) for 1 h, and then treated with 0.7 ml of secretagogue-containing medium (stimulation buffer: 10 mM HEPES, 79 mM NaCl, 5 mM NaHCO3, 50 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgCl2, 2 mM BaCl2, 2.8 mM glucose, pH 7.4) for 15min (27) . 500ll medium was collected and centrifuged for 5 min at 1,000g to remove the debris. The supernatants were concentrated by a protein concentrator with 10 kDa cut-off (Millipore), followed by western analysis. Secreted human (FLAG) or mouse SOD1, CHGB or CgB was estimated by standardization with intracellular human (FLAG) or mouse SOD1, CHGB or CgB in total cell lysates.
Animal models
All experimental procedures were carried out according to the Guide of Care and Use of Experimental Animals of the Canadian Council on Animal Care. The 18.8 kb full-length genomic fragments carrying CHGB (P413 or L413) (Fig. 1B) were microinjected in 1-day-old mouse embryos. The founders were bred with nontransgenic C57BL/6 mice to establish stable transgenic lines. The genomic integration of the transgene was confirmed by PCR from mouse ear DNA. The mRNA in the spinal cord was analyzed by quantitative real-time PCR (qRT-PCR), as described below. One line with a highest copy of CHGB mRNA was maintained as C57BL/6. The SOD1 G37R (line 29) transgenic mice were a gift from Drs.
P. Wong and D. Price from Johns Hopkins University (Baltimore, MD) and have been maintained as C57BL/6 in our laboratory (55) . Double transgenic mice over-expressing CHGB species and mutant SOD1 G37R were derived by breeding mice hemizygous for each of the CHGB generated transgene with SOD1 G37R mice.
The SOD1
G37R
;CHGB mice were then genotyped by two sets of PCR primers for CHGB and SOD1 G37R transgenes. The sequences of primers are shown in Supplementary Material, Table S4 . For clinical analyses, body weight and rotarod score were analyzed once a week starting at 200 days of age by investigators blinded to the genotype. The accelerating rotarod test was performed on mice at 4 rpm speed with 0.125 rpm/s acceleration. The length of time that mice stayed on the rod (up to a maximum of 4 min) was recorded as an indicator of grasping power. Three trials were performed and the best result was recorded. Using rotarod analysis, disease onset was determined as 30% loss of maximum recorded time (37, 38) . End-stage was defined as the time at which mouse could not right itself within 30 s when placed on its side.
Quantitative real time RT-PCR
Real-time RT-PCR was performed with a LightCycler 480 (Roche) sequence detection system using Light-Cycler SYBR green I at the Quebec Genomics Centre (56) . Total RNA was extracted from frozen spinal cord tissues using Qiazol reagent (miRNeasy, Qiagen, Valencia, CA). Total RNA was treated with DNase (Qiagen) to get rid of genomic DNA contaminations. Total RNA was the quantified using Nanodrop, and its purity was verified by Bioanalyzer 2100 (Agilent Technologies, Mississauga, ON, Canada). Gene-specific primers were constructed using the GeneTools software (Biotools, Jupiter, FL). Two genes, Atp5o and 18S were used as internal control genes. The primers used for the analysis of genes are given in Supplementary Material, Table S4 .
Immunofluorescence and immunohistochemistry of spinal cord and neuromuscular junction
Mice were anaesthetized and transcardially perfused with 0.9% NaCl and fixed with 4% paraformaldehyde (PFA) pH 7.4. Spinal cords and gastrocnemius muscles were dissected, post-fixed in 4% PFA pH 7.4 and then placed in phosphate-buffered saline (PBS)-sucrose 30% (55) . Spinal cords or gastrocnemius muscles were cut on microtome or cryostat (Leica, Richmond Hill, ON, Canada) in 25 lm sections. Spinal sections were incubated with PBS containing 4% goat serum or bovine serum albumin and 0.3% Triton-X100 for 1h at room temperature for blocking. After blocking, sections were incubated with primary antibodies diluted in PBS at room temperature overnight and subsequently with corresponding fluorescent secondary antibodies (Alexa, Invitrogen) or with biotinylated secondary antibodies visualized by the avidin-biotin-immunoperoxidase complex (ABC) method using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) and 3,3'-diaminobenzidine tetrahydrochloride (DAB; Vector). Gastrocnemius muscle sections were incubated with PBS containing 4% bovine serum albumin and 0.3% Triton-X100 for 30min at room temperature for blocking. After blocking, sections were incubated with anti-PGP9.5 (1:500) and anti-VAChT (1:500) antibodies diluted in PBS at room temperature overnight and subsequently with corresponding fluorescent secondary antibodies (Alexa, Invitrogen) and rhodamine conjugated aBungarotoxin (1:1,000). Samples were microscopically videocaptured or observed by confocal laser microscopy (LSM5 Pascal, Zeiss, Oberkochen, Germany). For the analysis of the number and size of a-motor neuron (MN) stained with both ChAT and NeuN and the semiquantitative evaluation of immunoractivity for Mac2 and GFAP, the average of number and size of a-MN and signal intensity in five lumbar cord sections from each mice (n ¼ 3-4 mice for each group) was analyzed using Image J. For the analyses of denervation, 100 neuromuscular junctions from each mouse were analysed (n ¼ 3 mice for each group). For the calculation of MN percentages expressing misfolded SOD1 or BiP, double positive MNs (MN markers was ChAT) and signal intensity values inside cells for the antigen of interest were calculated in five lumbar cord sections (n ¼ 3-4 mice for each group) (57) . Data of signal intensity were acquired using identical confocal settings.
Subcellular fractionation of the spinal cord lysates
Spinal cord tissues from CHGB transgenic mice were homogenized in a homogenization buffer consisting of 250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM MgCl2 and protease inhibitor cocktail (27) . The debris was excluded by centrifugation at 1,000 g for 15 min. After the pellet (mitochondrial fractions) was excluded by centrifugation at 8,000 g for 10 min, the supernatant (post-mitochondrial fractions) was ultracentrifuged at 100,000 g for 1 hr to separate into the supernatant (cytosolic fractions) and the pellet (microsome fractions). The pellet was lysed in the homogenization buffer containing 1% Triton X100 with brief osmication before protein determination.
Immunoblotting and immunoprecipitation of spinal cord lysates
The post-mitochondrial (cytoplasmic plus microsomal) fractions of spinal cords were prepared by the same protocol as subcellular fraction. B8H10 antibody (33) or anti-SOD1 polyclonal antibody (Santa Cruz) was bound to protein G-coated magnetic beads (Dyanl, Invitrogen, Camarillo) and was incubated with 50lg of spinal cords homogenized in TNG-T buffer or 150 lg of post-mitochondrial fractions of spinal cords overnight at 4 C (27). After washing, immunoprecipitates were eluted with SDS sample buffer. Immunoprecipitates were analyzed by Western blotting with SOD1-specific antibody (Enzo) or human CHGB (QED). Densitometries of misfSOD1 and Bip were analyzed using ImageJ and standardized with actin.
In situ hybridization of spinal cord
In situ hybridization procedures using digoxigenin-labelled cRNA probes for CHGB were performed as described previously (58) . Bright field images of sections of the lumbar cord were used for quantification of CHGB overexpression within the gray matter. The average of signal intensity in seven sections from each mouse (n ¼ 3 mice for each group) was analyzed using Image J.
Samples from study participants and genotyping
All participants were diagnosed by expert neurological clinicians and gave written informed consent. Diagnosis of ALS was made according to El Escorial criteria (59) . Peripheral blood samples from Japanese SALS patients (n ¼ 141) were collected in Okayama university. Those from ALS patients in Canada/ Quebec (non-SOD1 FALS ¼40, SALS ¼249), France (SALS ¼527) and in Swedish (FALS ¼163, SALS ¼290) were collected, as previously described (26, 28, 29) . The CHGB P413L were genotyped by restriction enzyme digestion, as previously described (28) . Polymerase chain reaction (PCR) primer pairs were designed to amplify a 500-bp PCR fragment in which the P413L variation is located in the middle of the PCR fragment (5'-aacgtcagcatggccagtttag -3' and 3'-acaagttgggtatgatgctgggag -5'). P413L variation abolished an Mspl restriction site. PCR fragments digested with Mspl (New England BioLabs) were run on agarose gel to confirm the presence or absence of the P413L variation.
Data analysis
Data are expressed as means 6 SEM. Statistical comparisons of data were performed using t-tests or one-way ANOVA followed by a Tukey-Kramer post hoc comparison. Kaplan-Meier survival analysis and the log-rank test were used for survival and comparison of onset. Statistical analyses were done using GraphPad Prism 5 (version 5.00; GraphPad Software, Inc., San Diego, CA). Statistical significance was set at P < 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
